Nuvation Bio (NUVB) Proxy filing summary

Executive summary

• Supplement corrects a typographical error in the previously filed proxy statement regarding non-employee director compensation for the 2025 fiscal year.

• The corrected compensation table provides updated cash and total compensation figures for non-employee directors.

Board of directors and corporate governance

• Non-employee directors received both cash compensation and option awards, with detailed amounts disclosed for each director.

• Dr. Cui voluntarily forfeited both his retainer and option awards for the year.

• As of December 31, 2025, most non-employee directors held options to purchase 292,983 shares, except Dr. Cui (none) and Dr. Mashal (560,632 shares).

Executive compensation and say-on-pay

• The corrected table reflects that Robert Mashal, M.D. received $47,500 in cash compensation, not $37,500 as previously reported, affecting his total compensation.

• Option awards were valued in accordance with FASB ASC Topic 718, with assumptions detailed in the annual report.